Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.

NEW YORK, June 17 (Reuters) - A unit of Merck & Co Inc has agreed to pay $5.9 million to resolve claims that it fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.